canada is a world leader in medical education scholarship, with achievements including problem-based learning (pbl), multiple mini-interviews (mmis), and the first national licensure objective structured clinical examination (osce). medical 世界杯2022赛程表淘汰赛 are in a unique position to contribute to the medical education literature. our personal experiences with the training curricula can shed light on what works and what doesn't, generating ideas and stimulating new research questions.

the ontario medical 世界杯2022赛程表淘汰赛 association (omsa) is excited to announce the sixth annual medical student education research grant (mserg) call for applications in partnership with the associated medical services (ams), oma insurance, the cma, and md financial management.

the 2020 mserg will provide grants valued at $5,000 each to fund nine projects designed by ontario medical 世界杯2022赛程表淘汰赛 . this will enable 世界杯2022赛程表淘汰赛 to conduct research projects in medical education. three of these nine awards will be granted in the open stream and six of these nine awards will be granted in the compassionate care steam. of the nine mserg awards, at least one award will go to a student project from each of the six ontario medical schools, provided that they meet the eligibility criteria.

the deadline to apply is april 13th, 2020.

the law foundation of ontario invites applications to apply for a measuring impacts and progress 2020 grant, through our strategic granting program.

the purpose of the measuring impacts and progress 2020 granting is to build the knowledge that will improve justice system services for the people of ontario. the first method is to support research or activities that address making improvements in the use of data in the justice system. the second is to support empirical research that will help improve how the justice system serves the people of ontario. this granting stream highlights the foundation’s objective of expanding knowledge: “we continually deepen our knowledge of access to justice, including the contribution of community organizations. we are committed to share our knowledge of what is happening and what works”.

the canadian frailty network (cfn) is looking to fund proposals aimed at investigating the interaction between frailty and covid-19. older adults living with frailty are the most vulnerable to covid-19. as a result, cfn is looking for health, social or policy research studies that investigate determinants of increased susceptibility, and solutions to mitigate or prevent the differential risk to covid-19. see below for specific proposal details.

the nih exploratory/developmental grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. these studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

the nih small research grant program supports small research projects that can be carried out in a short period of time with limited resources. this program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

this funding opportunity announcement does not accept applications proposing clinical trial(s).

the fy20 defense appropriation act provides $15 million to the department of defense orthotics and prosthetics outcomes research program (oporp) to support research on outcomes-based best practices through analysis of the merits of prosthetic and orthotic device options currently available, not on the development of new or the improvement of existing technology. as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the managing agent for the anticipated program announcement/funding opportunity is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 oporp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. pre-application and application deadlines will be available when the program announcements are released. 

oporp supports research that evaluates orthoses and/or prostheses using patient-centric outcomes relevant to service members and veterans with limb loss and/or limb impairment. the intent of this research is to generate clinically useful evidence that will enhance and optimize patient outcomes. applications submitted to the fy20 oporp must address at least one of the following focus areas:

• orthoses or prostheses form: optimize patient outcomes through the analysis and characterization of variables related to the form of currently available clinical options such as device size, shape, material, and/or configurations.

• orthoses or prostheses fit: optimize patient outcomes related to human-device interface through the analysis of variables in currently available clinical options that facilitate fit-related metrics such as comfort and/or usability.

• orthoses or prostheses function: optimize patient outcomes through the analysis of variables related to currently available device function such as device control, sensors, and passive or active response with respect to activities of daily living and other real-world activities.

https://cdmrp.army.mil/funding/oporp

clinical research award – letter of intent due june 10, 2020

independent investigators at all academic levels (or equivalent).

• supports research that evaluates orthoses and/or prostheses using patient-centric outcomes relevant to service members, veterans, and other individuals with limb loss and/or limb impairment.
• supported research is intended to generate clinically useful evidence with potential to enhance and optimize patient outcomes.
• multidisciplinary collaboration among academics, industry, patient advocacy, the military services, the department of veterans affairs (va), and/or other federal government agencies is highly encouraged.
• applications submitted to the fy20 oporp cra must address one or more of the fy20 oporp focus areas.
• preclinical studies using animals are not allowed.
• clinical trials are not allowed.
• the fy20 cra offers two funding levels:

• funding level 1
• maximum funding of $350,000 for total costs (direct plus indirect costs).
• maximum period of performance is 2 years.
• funding level 2
• maximum funding of $2,000,000 for total costs (direct plus indirect costs).
• maximum period of performance is 4 years.

clinical trial award – letter of intent due june 10, 2020

independent investigators at all academic levels (or equivalent).

• supports implementation of clinical trials with the potential to have a significant impact on improving the health and well-being of service members, veterans, and other individuals living with limb loss and/or limb impairment.
• supports clinical trials that evaluate orthoses and/or prostheses using patient-centric outcomes for the purpose of generating clinically useful evidence to enhance and optimize patient outcomes.
• multidisciplinary collaborations among academia, industry, patient advocacy, the military services, va, and/or other federal government agencies is highly encouraged.
• applications submitted to the fy20 oporp cta must address one or more of the fy20 oporp focus areas.
• funding level 1 supports pilot clinical trials which are exploratory and involve limited human exposure with the potential to make significant advancement toward clinical translation. preliminary data are allowed but not required.
• funding level 2 supports clinical trials with the potential to make significant advancement toward clinical translation. preliminary data relevant to the proposed clinical trial are required.
• preclinical research is not allowed.
• the fy20 cta offers two funding levels:

• funding level 1
• funding level 2
• maximum period of performance is 4 years.

• maximum funding of $350,000 for total costs (direct plus indirect costs).
• maximum period of performance is 2 years.

• maximum funding of $4,000,000 for total costs (direct plus indirect costs).

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website. the application package containing the required forms for each award mechanism will also be found on grants.gov. a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org. for more information about the oporp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

department of defense neurofibromatosis research program

funding opportunities for fiscal year 2020 (fy20)

the fy20 defense appropriations act is providing funding to the department of defense neurofibromatosis research program (nfrp) to support innovative, high-impact nf research.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

fy20 nfrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

areas of emphasis: the nfrp encourages applications that specifically address the critical needs of the nf community in one or more of the fy20 areas of emphasis.  not all areas of emphasis are applicable to each award mechanism offered by the fy20 nfrp.  if the proposed research project does not address one of the fy20 areas of emphasis, justification that the proposed research project addresses an important problem related to nf research and/or patient care should be provided. applications submitted to the fy20 nfrp must address one or more of the following areas of emphasis:

• biomarker discovery, utility, development, and validation
• non-tumor manifestations not limited to:

o  pain

o  cognitive manifestations

o  sleep

• heterogeneity of nf-related tumors
• novel disease and treatment response markers using genetics, genomics, epigenetics, systems biology, metabolomics, or similar approaches
• preclinical efficacy studies
• target identification, drug discovery
• nutritional, environmental, and other modifiers of nf
• health services research

https://cdmrp.army.mil/funding/nfrp

clinical trial award – letter of intent due june 25, 2020

must be at or above the level of assistant professor (or equivalent)

• supports research with the potential to have a major impact on the treatment or management of neurofibromatosis (nf).
• funds phase 0, i, or ii clinical trials relevant to nf and/or schwannomatosis.  combinations of phases are permitted.
• must support a clinical trial and may not be used for preclinical research studies.
• the maximum allowable funding for the entire period of performance is $800,000 in direct costs ($1,000,000 in direct costs if requesting the qualified collaborator option)
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• the maximum period of performance is 4 years

exploration – hypothesis development award – letter of intent due june 25, 2020

investigators at all academic levels (or equivalent)

• supports the initial exploration of innovative, high-risk, high-gain concepts and potentially groundbreaking concepts in nf research.
• preliminary and/or published data is encouraged but not required.
• projects involving human subjects or human anatomical substances must be exempt under 32 cfr 219.104(d) or eligible for expedited review under 32 cfr 219.110 or 21 cfr 56.110.
• clinical trials not allowed.
• the maximum allowable funding for the entire period of performance is $100,000 for direct costs.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• the maximum period of performance is 2 years

new investigator award – letter of intent due june 25, 2020

must be either:

an independent investigator at or below the level of assistant professor (or equivalent) and must plan to commit at least 30% of his/her effort toward the proposed research project;

or

an established independent investigator in an area other than nf at or above the level of assistant professor seeking to transition into a career in nf research and must plan to commit at least 10% of his/her effort toward the proposed research project.

to be eligible, applicants may not have received more than $300,000 in direct costs for nf research as a principal investigator of one or more federally funded, non-mentored peer reviewed grants.

• supports the continued development of promising independent investigators and/or the transition of established investigators from other research fields into a career in nf research.
• prior experience in nf research is not required.
• preliminary and/or published data relevant to nf and the proposed data research project is required.
• clinical trials not allowed
  • the maximum allowable funding for the entire period of performance is $450,000 in direct costs.
  • indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
  • the maximum period of performance is 3 years

early investigator research award – letter of intent due june 25, 2020

the investigator must:

be involved in a postdoctoral training or medical residency programs, and

possess at least 1 and up to 4 years of continuous postdoctoral research experience by the early investigator research award application submission deadline: and

possess a doctoral degree (i.e., ph.d, m.d./ph.d, d.o./ph.d) or a clinical doctoral degrees (i.e., m.d./d.o. or ph.d. in a clinical discipline) from an accredited organization or program.

• supports nf-focused research opportunities for individuals in the early stages of their careers.
• investigators must have a designated mentor who is an experienced nf researcher.
  • the maximum allowable funding for the entire period of performance is $200,000 in direct costs.
  • indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
  • the maximum period of performance is 2 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the nfrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org